US Patent Issued to Takeda Pharmaceutical on March 31 for "Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments" (Massachusetts Inventors)

ALEXANDRIA, Va., March 31 -- United States Patent no. 12,590,157, issued on March 31, was assigned to Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments" was invented by Rachael L. Brake (Natick, Mass.) and Eric H. Westin (Concord, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides, inter alia, methods of reducing gastrointestinal immune-related adverse events, such as colitis and diarrhea, in subjects undergoing an immune treatment, such as an immune oncology treatment, such as anti-CTLA4 antibody and anti-PD-1 antibody combination treatment for melanoma. In certain aspects, the methods enc...